CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 53 enrolled
Drug / intervention
sunitinib malatedrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00474994
NCT00474994Phase 2Completed
CompareCT.gov

A Multicenter Phase II Study of Continuous Dosing of Sunitinib (Sutent®, SU11248) in Non-GIST Sarcomas

Memorial Sloan Kettering Cancer Center·interventional·Posted May 17, 2007·Updated Jan 20, 2016

In Brief

A Phase 2 clinical trial evaluating sunitinib malate for Adult Malignant Fibrous Histiocytoma of Bone and 5 related conditions. Completed, enrolled 53 participants across 2 sites.

Detailed Summary

RATIONALE: Sunitinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor. PURPOSE: This phase II trial is studying how well sunitinib works in treating patients with metastatic, locally advanced, or locally recurrent sarcomas.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAdult Malignant Fibrous Histiocytoma of Bone, Desmoid Tumor, Endometrial Cancer, Ovarian Cancer, Sarcoma, Small Intestine Cancer
CountriesUnited States
CollaboratorsNational Cancer Institute (NCI), Dana-Farber Cancer Institute

Timeline

Phase 2CompletedFinished
200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedMay 17, 2007
Enrollment StartApr 1, 2007
Primary CompletionNov 1, 2010
TodayJul 2, 2026
Enrollment to primary: 3.6 yearsPosted 19.1 years ago

Interventions

sunitinib malatedrug